Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;50(12):1885-1894.
doi: 10.1002/eji.202048820. Epub 2020 Dec 2.

Checkpoints controlling the induction of B cell mediated autoimmunity in human autoimmune diseases

Affiliations
Free article
Review

Checkpoints controlling the induction of B cell mediated autoimmunity in human autoimmune diseases

S Reijm et al. Eur J Immunol. 2020 Dec.
Free article

Abstract

B cell targeting therapies are effective in various autoimmune diseases, among others rheumatoid arthritis, pemphigus vulgaris, and systemic lupus erythematosus. Given these successes, it is evident that B cells are central orchestrators in the processes leading to the signs and symptoms hallmarking many human autoimmune diseases. The pathways provoking the generation of such autoreactive B cells or mechanisms preventing their induction in health are, however, poorly explored. Nevertheless, such information is crucial for the development of preventative/curative interventions aiming to permanently deplete- or prohibit the emergence of autoreactive B cells. Hence, this review will focus on how B cell tolerance might be breached, and which checkpoints are at play preventing the arousal of autoreactive B cells in human. Especially antigen presentation by follicular dendritic cells, somatic hypermutation, and cross-reactivity to the microbiome/environment could operate as actors playing pivotal roles in the induction of B cell-mediated humoral autoimmunity. Moreover, we highlight the human autoimmune disease rheumatoid arthritis as a prototype where autoreactive B cells combine several mechanisms to overcome peripheral B cell checkpoints.

Keywords: autoimmunity; cross presentation/priming; regulatory T cells; rheumatology; tolerance.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Edwards, J. C. and Cambridge, G., Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology (Oxford) 2005. 44: 151-156.
    1. Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M. and Shaw, T., Efficacy of B-Cell-Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis. N. Engl. J. Med. 2004. 350: 2572-2581.
    1. Joly, P., Maho-Vaillant, M., Prost-Squarcioni, C., Hebert, V., Houivet, E., Calbo, S., Caillot, F. et al., First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet North Am. Ed. 2017. 389: 2031-2040.
    1. Musette, P. and Bouaziz, J. D., B cell modulation strategies in autoimmune diseases: new concepts. Front. Immunol. 2018..
    1. Hampe, C. S., B Cell in Autoimmune Diseases. Scientifica (Cairo) 2012. 2012.

Publication types

LinkOut - more resources